Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027

The US FDA accepted Unicycive Therapeutics' New Drug Application for an investigational treatment for hyperphosphatemia.